https://www.selleckchem.com/Proteasome.html
We are developing cancer immunotherapy based on the use of autologous tumor tissue that has been rendered replication-incompetent but maintains phenotype and metabolic activity post-preparation. The aim of this study was to evaluate safety and tolerance to injection of the inactivated tumor cell and adjuvant preparation (Innocell™) within 24 hours of administration in a pilot study in canine patients with solid organ tumors. . Three canine patients demonstrating accessible solid organ tumors of various types were assessed in this study. The l
Like
Comment
Share
